KIRKLAND, Wash.--(BUSINESS WIRE)--Medical device innovator Cardiac Insight, Inc. has closed a $2.5 million Series C capital funding. A University of Washington spinoff, the privately-held company focuses on advanced cardiac and respiratory sensing and computing technologies. Proceeds will be used to accelerate the market penetration of the company’s CardeaScreen™ product and finalize the development of the company’s proprietary wearable sensor technology.
CardeaScreen helps identify young athletes who may be at risk for sudden cardiac arrest (SCA). A 12-lead electrocardiogram (ECG) exam takes less than 20 seconds. The company’s patented wireless hand-held device and advanced analysis software then assists physicians to determine the need for further evaluation prior to participation in strenuous activities.
“We are excited to have completed this funding and move forward with our near term FDA submission for our 7-day ECG Monitor and increasing the sales of our CardeaScreen 12-lead device. Cardiac Insights' shareholders and our partners look forward to both products serving patients by the end of 2016,” says Brad Harlow, CEO of the company.
CardeaScreen diagnostic algorithms have substantially reduced the rate of false positive indications. This breakthrough makes the non-invasive screening cost-effective for schools and is emerging as a best practice for pre-participation examinations by pediatricians and family practice physicians.
Cardiac Insight is also engaged in the development of single-use, patient-centric technologies to simplify and streamline complex diagnostic exams centered around cardiology and related practices.
Further information is available online at www.cardiacinsightinc.com.
